SEARCH

SEARCH BY CITATION

References

  • 1
    DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794811.
  • 2
    Cramer JA. Partial medication compliance: the enigma in poor medical outcomes. Am J Manag Care 1995;1:4552.
  • 3
    Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2000;2:51014.
  • 4
    Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: cross-national study. JAMA 1998;279:145862.
  • 5
    Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharm J 2004;272:140.
  • 6
    Urquhart J. Defining the margins for errors in patient compliance with prescribed drug regimens. Pharmacoepidemiol Drug 2000;9:5658.
  • 7
    Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. In: Cramer, JA, Spilker, B, eds. Compliance in Medical Practice and Clinical Trials. New York: Raven Press, 1991.
  • 8
    Feinstein AR. On white coat effects and the electronic monitoring of compliance. Arch Intern Med 1990;150:13778.
  • 9
    Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:10038.
  • 10
    Sackett DL, Haynes RB. Compliance with Therapeutic Regimens. Baltimore, MD: The Johns Hopkins University Press, 1976.
  • 11
    Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization, 2003. Available from: http://www.who.int/chronic_conditions/en/adherence_report.pdf[Accessed July 2, 2006].
  • 12
    Cramer JA. Relationship between medication compliance and medical outcomes. Am J Health Syst Pharm 1995;52(Suppl.):S529.
  • 13
    Lopatriello S, Berto P, Cramer JA, et al. Different aspects of adherence to antihypertensive treatments. Exp Rev Pharmacoeconom Res 2004;4:3173.
  • 14
    Roter DL, Hall JA, Rolande M, et al. Effectiveness of interventions to improve patient adherence: a metaanalysis. Med Care 1998;36(8):113861.
  • 15
    Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:18814.
  • 16
    Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:32737.
  • 17
    Claxton AJ, Cramer JA, Pierce C. Medication compliance: the importance of the dosing regimen. Clin Ther 2001;23:1296310.
  • 18
    Catalan VS, LeLorier J. Predictors of long term persistence on statins in a subsidized clinical population. Value Health 2000;3:41726.
  • 19
    Yanni F, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medication for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005;8:495505.
  • 20
    Cramer JA, Amonkar MM, Hebborn A, Altman RD. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:145360.
  • 21
    White TJ, Chang E, Leslie S, et al. Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. J Manag Care Pharm 2002;8:18691.
  • 22
    Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005;11:2319.
  • 23
    Grant RW, O'Leary KM, Weilburg JB, et al. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004;164:23438.
  • 24
    Cramer JA, Sernyak M. Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate. Clin Ther 2004;26:90514.
  • 25
    Malone M, Alger-Mayer SA. Pharmacist intervention enhances adherence to Orlistat therapy. Ann Pharmacother 2003;37:1598602.
  • 26
    Carswell JL, Beard KA, Chevrette MM, et al. Tracking trends in secondary stroke prevention strategies. Ann Pharmacother 2004;38:21519.
  • 27
    Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:44957.
  • 28
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records. Methods, validity, and applications. J Clin Epidemiol 1997;50:10516.
  • 29
    Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:312.
  • 30
    Burrell A, Wong P, Ollendorf D, et al. Defining compliance/adherence and persistence: ISPOR Special Interest Working Group. Value Health 2005;8:A1945.